Download - Glenmark

More documents

Recommendations

Info

Consolidated Statement of Comprehensive Income (All amounts in millions of Indian Rupees, unless otherwise stated) Consolidated Income Statement Notes Year e nded 31 March 2011 Revenues Operating Revenue P 29,490.70 Other income Q 1,405.18 Total Revenues 30,895.88 Expenses Materials consumed R 9,918.32 Employee costs S 5,103.03 Other expenses 8,546.64 Depreciation and amortisation H & I 946.78 Total Expenses 24,514.77 Operating profit 6,381.11 Finance income 38.97 Finance costs (1,604.55) Profit befo re tax 4,815.53 Taxes Current tax expenses N 504.92 Deferred tax credit N (267.72) Profit for the year 4,578.33 Profit for the year attributable to: Non-controlling interest 46.25 Equity shareholders of Glenmark Pharmaceuticals Limited 4,532.08 Earnings per share Basic (in `) W 16.78 Diluted (in `) W 16.76 (The accompanying notes are an integral part of these consolidated financial statements) For Walker, Chandiok & Co. Chartered Accountants For and on behalf of the Board of Directors Khushroo B. Panthaky Glenn Saldanha Cheryl Pinto Partner Chairman & Managing Director Director Place: Mumbai Date: 10 May 2011 Marshall Mendonza Vice President - Legal & Company Secretary 80 GLENMARK PHARMACEUTICALS LIMITED
Consolidated Statement of Comprehensive Income (All amounts in millions of Indian Rupees, unless otherwise stated) Consolidated Statement of Other Comprehensive Income Note Year ended 31 March 2011 Profit for the year 4,578.33 Other comprehensive income Exchange differences on translating foreign operations O (1,249.33) Income tax relating to components of other comprehensive income - Other comprehensive income for the year, net of tax (1,249.33) Total comprehensive income for the year 3,329.00 Total comprehensive income attributable to: Non-controlling interest 46.25 Equity shareholders of Glenmark Pharmaceuticals Limited 3,282.75 (The accompanying notes are an integral part of these consolidated financial statements) Consolidated Statement of Changes in Shareholders' Equity (All amounts in millions of Indian Rupees, unless otherwise stated) Common stock – No. of shares Equity attributable to shareholders of Glenmark Pharmaceuticals Limited Common Additional Stock Statutory Currency Accumulated stock - paid-in compensation reserve Translation earnings Amount capital reserve reserve Total attributable to owners of the parent company Noncontrolling interest Total stockholders’ equity Balance as at 1 April 2010 269,837,553 269.84 7,643.87 133.91 201.00 (169.93) 9,178.77 17,257.46 264.23 17,521.69 Translation adjustment - - - - - (1,249.33) - (1,249.33) - (1,249.33) Income/ (expense) recognised directly in equity - - - - - (1,249.33) - (1,249.33) - (1,249.33) Net income for the year - - - - - - 4,532.08 4,532.08 46.25 4,578.33 Total income and expense recognised for the year - - - - - (1,249.33) 4,532.08 3,282.75 46.25 3,329.00 Tax impact on share issue expenses - - 20.32 - - - - 20.32 - 20.32 Employee share based compensation - - - 82.71 - - - 82.71 - 82.71 Acquisition of noncontrolling interest - - - - - - (185.36) (185.36) (43.47) (228.83) Shares issued under Employee Stock Option (‘ESOP’) Scheme 434,500 0.43 56.71 (16.28) - - - 40.86 - 40.86 Dividends paid - - - - - - (126.37) (126.37) - (126.37) Balance as at 31 March 2011 270,272,053 270.27 7,720.90 200.34 201.00 (1,419.26) 13,399.12 20,372.37 267.01 20,639.38 (The accompanying notes are an integral part of these consolidated financial statements) For Walker, Chandiok & Co. Chartered Accountants For and on behalf of the Board of Directors Khushroo B. Panthaky Glenn Saldanha Cheryl Pinto Partner Chairman & Managing Director Director Place: Mumbai Date: 10 May 2011 Marshall Mendonza Vice President - Legal & Company Secretary Annual Report 2010-2011 81
Page 35 and 36: Profiles of Directors Mr. Gracias S
Page 37 and 38: DIRECTORS Mr. D. R. Mehta, Mrs. B.
Page 39 and 40: 3. Metformin ER Tablets 1000 mg 4.
Page 41 and 42: ANNEXURE - B Disc losure in the Dir
Page 43 and 44: Report on Corporate Governance Purs
Page 45 and 46: 5. Shareholders’/Investors’ Gri
Page 47 and 48: Distribution Schedule as on 31 Marc
Page 49 and 50: Market Price Data: High, low during
Page 51 and 52: Certification by the Chief Executiv
Page 53 and 54: Auditors’ Report To, The Members
Page 55 and 56: (b) The dues outstanding in respect
Page 57 and 58: Profit and Loss Account (All amount
Page 59 and 60: Cash Flow Statement (All amounts in
Page 61 and 62: Schedules annexed to and forming pa
Page 81 and 82: Additional information as required
Page 83: Consolidated Statement of Financial
Page 87 and 88: Notes to Consolidated Financial Sta
Page 89 and 90: the foreign entity and translated i
Page 91 and 92: The Group’s internal drug develop
Page 93 and 94: Financial liabilities are recognise
Page 95 and 96: In those cases where the possible o
Page 97 and 98: NOTE B - BASIS OF CONSOLIDATION The
Page 99 and 100: NOTE H - PROPERTY, PLANT AND EQUIPM
Page 101 and 102: Working Capital Facilities is secur
Page 103 and 104: NOTE R - MATERIALS CONSUMED Materia
Page 105 and 106: Net compensated absence cost for th
Page 107 and 108: NOTE Y - SEGMENT REPORTING The Chie
Page 109 and 110: The Group’s trade and other recei
Page 111 and 112: As at 31 March 2011, the Group’s
Page 113 and 114: Depreciation Further, depreciation
Page 116 and 117: GLENMARK PHARMACEUTICALS LIMITED Re
Page 118: GLENMARK PHARMACEUTICALS LIMITED Re

Download - Glenmark

Create successful ePaper yourself

Delete template?

Save as template?